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Abstract 
Background 
 
Driveline infections (DLI) are a significant cause of morbidity and mortality in 
ventricular assist device (VAD) recipients. We compared driveline infection (DLI) 
rate after an institutional change in driveline management protocol. 
 
Methods 
 
We retrospectively reviewed records of left VAD recipients at our institution, 
based on driveline management. Group 1: daily driveline dressing change 
consisting of chlorhexidine cleansing, sterile 4x4 gauze, and use of an abdominal 
binder. Group 2: Dressing change every 3 days consisting of chlorhexidine 
cleansing, non-sterile silver-impregnated foam with overlying clear dressing, and 
use of a driveline anchor. Follow-up was censored at first DLI, device removal, 
transplant or death. Additionally, Group 1 patients’ follow-up was censored when 
the change in protocol occurred. Statistical analysis: Student’s t-test, Fisher’s 
exact test, Kaplan-Meier curve and log-rank test. 
 
Results 
 
DLI occurred in 16% of 88 VAD recipients (Group 1 n=24, Group 2 n=64). The 
new driveline management protocol resulted in significantly fewer DLI in Group 2 
(6.3% vs. 41.7%, p<0.0001) 
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Conclusions 
 
An updated driveline management protocol demonstrated significant reduction in 
DLI at our institution. Studies evaluating the optimal approach for driveline 
management are needed in order to develop a standardized regimen aimed at 
lowering the risk of DLI. 
Keywords 
Ventricular assist device; driveline infection; driveline dressing; infection 
prevention 
Introduction  
 
Heart failure is a major cause of morbidity and mortality in the United States, 
where about 5.1 million people are living with heart failure; half of these patients 
will die within 5 years of diagnosis.(1) Ventricular assist devices (VADs) have 
emerged as a standard of care for patients with end-stage heart failure, both as a 
bridge to transplant (BTT) and as destination therapy (DT) with actuarial survival 
of 80% at one year and improved quality of life.(2) However, VAD use is 
associated with various complications, including percutaneous driveline 
infections (DLIs).    
 
Overall rate of DLI in various studies ranges from 14-48%; infections appear to 
be cumulative over time with increased DLI noted with greater duration of VAD 
support.(3-5) DLIs negatively impact recipient quality of life; potential 
complications include development of sepsis/ bacteremia, hospital re-
admission(s), pump pocket infection, re-operation, and decreased survival.(3, 4, 
6) Risk factors for DLI include obesity, diabetes, younger age, trauma to the 
driveline site, and length of implantation.(4-6) 
 
Currently there are no standardized protocols for the type of driveline dressing 
used or the frequency of change; VAD centers in the United States use a variety 
of protocols.(7) Current measures to decrease the rate of DLI include tunneling 
the driveline within the abdominal subcutaneous tissue, stabilization of the 
device, and use of various dressing change protocols. Stabilization of the 
driveline has generally been achieved with the use of abdominal binders. A 
recent survey of VAD coordinators among 38 US centers showed that 70% of the 
responding centers used a stabilization belt.(7) Several recent papers discuss 
alternative stabilization techniques for the driveline such as use of StatLock 
system with a silicone suture, Centurion Foley anchor, or Hollister tube holder 
instead of the abdominal binder that is easier and more comfortable for the 
patient to use.(7, 8) The same survey also noted that there was no standard for 
dressing change protocols in terms of agents used and the frequency of dressing 
changes though 60% of programs reported daily dressing changes. It is also not 
clear if sterile technique should be applied at each dressing change.  
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We describe the results of a change in the management strategy of the driveline 
and the resultant significant decrease in DLIs observed at our institution.  
 
Methods  
 
After obtaining IRB approval, we retrospectively reviewed medical records for all 
patients that received a left ventricular assist device from 9/1/2010 to 5/30/2015 
at our institution. The IRB determined that informed consent was not required. 
We abstracted data regarding the indication for device placement, INTERMACS 
profile, baseline demographics, driveline management protocol, development of 
driveline infection and its microbiology, post-operative complications, length of 
hospital stay, duration of follow-up, and mortality. INTERMACS profile is a 
marker of severity of heart failure and ranges from 1-7; profile 1 is critical 
cardiogenic shock and profile 7 is consistent with advanced New York Heart 
Association functional class III heart failure.(9) We excluded all other infections 
such as VAD pump infection, mediastinitis, bloodstream infection, pneumonia, 
urinary tract infection etc. 
 
Definition of DLI: We used the standardized definitions put forth by the 
International Society of Heart and Lung Transplantation (ISHLT) in 2011.(10) 
Briefly, findings on surgery (if performed), growth of an organism on aseptic 
culture, clinical signs/ symptoms, and wound appearance are combined to define 
a superficial or deep DLI. For purposes of our study, we combined superficial and 
deep DLI into one category.  
 
VAD surgery: During the study period, our center implanted two types of durable 
continuous flow ventricular assist devices – HeartMate II (Thoratec Corporation, 
Pleasanton, CA) and HeartWare HVAD system (HeartWare, Framingham, MA). 
Two main cardiothoracic surgeons performed the surgeries according to 
established surgical technique. The driveline was tunneled in the subcutaneous 
tissue with the exit site generally on the right abdominal wall. The velour portion 
of the driveline was consistently placed under the skin in all patients. 
Perioperative antibiotic prophylaxis consisted of vancomycin and cefepime that 
was started within one hour prior to surgical incision and continued for 48 hours 
thereafter. Prior to 9/2012, we used cefazolin as peri-operative prophylaxis, 
which was continued for 48 hours post-operatively as well.  
 
Driveline Management Protocol: We compared two non-concurrent cohorts of 
patients based on their driveline management protocol.  
 
Group 1- The driveline dressing change occurred daily and consisted of 
chlorhexidine cleansing (ChloraPrep® One-Step, CareFusion, USA) and sterile 
4x4 gauze followed by the placement of an abdominal binder. This was the 
management protocol for patients that underwent VAD implantation from 
9/1/2010 to 8/31/2012.  
 
Group 2 - The driveline dressing changes were done every 3 days and consisted 
of chlorhexidine cleansing (ChloraPrep® One-Step, CareFusion, USA), silver-
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impregnated foam (Mepilex® Ag, Molnlycke Healthcare Sweden) which was then 
covered by a clear dressing (Centurion® Sorbaview® Shield, Centurion Medical 
Products Corp, USA) and placement of an “anchor” (Centurion® Foley Anchor, 
Centurion Medical Products Corp, USA) to prevent excess driveline movement 
(instead of the abdominal binder). This management protocol went into effect 
from 9/1/2012 to the current time.  
 
Patients and families were instructed on how to care for the driveline at home 
prior to hospital discharge and this teaching was reiterated at clinic visits by the 
VAD coordinators. If patients developed redness, pain, drainage from the 
driveline and/ or fever or other symptoms consistent with sepsis, they were 
thoroughly evaluated to look for a source of infection and possible VAD 
involvement. This work-up included blood cultures, aseptic culture of drainage 
from the driveline (if applicable) and imaging (echocardiogram/ computed 
tomography scan and/ or ultrasound).  
 
We censored follow-up at the occurrence of first driveline infection, removal of 
the device, transplantation or death. In addition, follow-up of Group 1 patients 
was censored at the time the institutional change in dressing protocol occurred; 
thus Group 1 only includes the time at risk as the time the patient was 
undergoing the management strategy for Group 1.  Figure 1 shows pictures of 
both types of dressings.  
 
Figure 1. Pictures of the driveline dressing in Group 1 (a) and Group 2 (b).  
 
 
Statistical analysis:  Univariate analyses were performed via t test or Fischer’s 
exact test as appropriate. Logistic regression was performed for multivariate 
analysis of factors that were associated with development of DLI in univariate 
analysis.  Kaplan-Meier survival analysis was used for estimating freedom from 
first DLI. Log-rank test was used to compare infection-free survival differences 
among groups. Patients who did not experience DLI were censored if they died, 
were transplanted, explanted for recovery, or lost to follow-up. We used Stata 
(Statacorp, College Station, Texas) as the software for analysis. 
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Results 
 
During the study period, 88 patients underwent left VAD placement (64 
HeartMate II, 24 HeartWare HVAD). Of these, 5 patients underwent device 
exchange for device thrombosis (4 HeartMate II, 1 HeartWare HVAD) and 7 
patients had concurrent right VADs (7 HeartWare HVAD). There were 24 patients 
in Group 1 and 64 patients in Group 2.  
 
Baseline characteristics at the time of VAD implantation are detailed in Table 1, 
including demographics, INTERMACS profile, underlying cardiomyopathy, other 
co-morbidities, basic laboratory parameters, and length of initial hospitalization at 
which the device was placed. The main differences between the two groups were 
in the indication for VAD implantation (Group 1 had 75% of DT patients vs. 
46.9% in Group 2, p=0.029), the type of device (Group 1 had 100% HeartMate II 
vs. 62.5% in Group 2, p<0.0001) and INTERMACS category (Group 1 had 8.3% 
INTERMACS category 4 vs. 31.3% in Group 2, p=0.029). Other parameters, 
including age, race, sex, underlying cardiac disease, co-morbidities, need for 
hemodialysis, length of hospitalization at index surgery, and return to the 
operating room were similar in both groups. 
 
Table 1. Baseline demographics of the study population.  
Group 1 patients underwent daily driveline dressing change consisting of 
chlorhexidine cleansing and sterile 4x4 gauze followed by the placement of an 
abdominal binder. Group 2 patients underwent driveline dressing changes every 
3 days consisting of chlorhexidine cleansing followed by a non-sterile silver-
impregnated dressing which was then covered by a clear dressing, and 
placement of an “anchor” to prevent excess driveline movement (instead of the 
abdominal binder). 
 
 Group 1 
(n=24) 
Group 2  
(n=64) 
p-value 
Age in years, mean 
(SD) 
58.25 (14.9) 58.2 (14) NS 
Male sex (%age) 17 (70.8%) 54 (84.4%) NS 
Race (%age) 
  Caucasian 
  African-American 
  Asian 
  Other   
 
 
18 (75%) 
3 (12.5%) 
2 (8.3%) 
1 (4.2%) 
 
 
31 (48.4%) 
12 (18.8%) 
5 (7.8%) 
16 (25%) 
 
NS 
Hispanic ethnicity 
(%age) 
4 (16.7%) 16 (25%) NS  
INTERMACS profile at 
time of implantation 
   1 
   2 
   3 
   4 
 
 
4 (16.7%) 
12 (50%) 
6 (25%) 
2 (8.3%) 
 
 
18 (28.1%) 
14 (21.9%) 
12 (18.8%) 
20 (31.3%) 
0.021 
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Indication 
   Bridge to transplant 
   Destination therapy 
 
6 (25%) 
18 (75%) 
 
34 (53.1%)  
30 (46.9%) 
0.029 
Type of VAD 
   HeartMate II 
   HeartWare 
 
24 (100%) 
0 
 
40(62.5%) 
24 (37.5%) 
<0.0001 
Primary disease 
   Ischemic 
   Non-ischemic 
 
11 (45.8%) 
13 (54.2%) 
 
25 (39.1%) 
39 (60.9%) 
NS  
Co-morbidities at time of 
VAD placement   
   Diabetes 
   CVA 
   Cirrhosis 
   COPD 
 
 
7 (29.2%) 
0 
0 
2 (8.3%) 
 
 
27 (42.2%) 
4 (6.3%) 
10 (15.6%) 
11 (17.2%) 
 
 
NS 
NS 
NS 
NS  
Body Mass Index, mean 
(SD) 
26.6 (4.3) 26 (0.7) NS  
Baseline laboratory 
parameters (with SD) 
 Sodium, mmol/L 
 Creatinine, mg/dL 
 WBC, 103 /mm3 
 HCT, % 
 Platelets, 103 /mm3 
 Bilirubin, mg/dL 
 Albumin, g/dL 
 INR 
 HbA1c 
 
 
133 (5.7) 
1.4 (0.5) 
8.8 (3.5) 
34.5 (5.3) 
205.5(53.7) 
1.5 (1.4) 
3.7 (0.4) 
1.3 (0.3) 
6.2 (0.6) 
 
 
132.8 (6.7) 
1.4 (0.48) 
8.6 (3.8) 
32.5 (5.4) 
199 (84.3) 
1.4 (1.3) 
3.6 (0.6) 
1.5 (0.4) 
6.2 (0.6) 
 
 
NS  
NS 
NS 
NS 
NS  
NS  
NS  
NS 
NS 
Post-VAD dialysis 
during index 
hospitalization 
3 (12.5%) 5 (7.8%) NS 
Mean length of index 
hospitalization in days, 
(SD) 
35.9 (35) 44.3(50.3) NS 
Previous cardiac 
surgery 
11 (45.8%) 17 (26.6%) NS  
Return to operating 
room within 30 days of 
index surgery 
4 (16.7%) 5 (7.8%) NS  
 
*INTERMACS profile 1 – critical cardiogenic shock; INTERMACS profile 2 – 
progressive decline in heart failure despite intravenous inotropic support; 
INTERMACS profile 3- stable heart failure but dependent on intravenous 
inotropic support; INTEMACS profile 4- resting heart failure symptoms but 
without intravenous inotropic support.  
Driveline Infections:  As seen in Table 2, the change in driveline management 
protocol resulted in a significant reduction in driveline infections in Group 2 vs. 
Group 1 (6.3% vs. 41.7%, p<0.0001) along with a significant decrease in the 
incidence of DLI/ 1000 device days; 0.24 vs. 1.81, p= 0.0002. Kaplan-Meier 
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survival curves (Figure 2) demonstrated significantly increased infection-free 
survival in Group 2 patients; log-rank test, p=0.0003. The mean onset of DLI in 
group 1 was 217.1 days vs 74.8 days in Group 2; this was not statistically 
significant (p=0.12).    
The overall mortality rate during the time of device placement was 11.4% (n=10) 
and was unrelated to the development of a DLI.  The relative risk reduction due 
to the new driveline management protocol was 85% and the number needed to 
treat was 2.82. 
Table 2. Occurrence of driveline infections (DLI) in the two cohorts of patients.  
 
 Group 1 (n=24) Group 2 (n=64) p-value 
No. of driveline 
infections 
10 (41.7%) 4 (6.3%) <0.0001 
Days of device follow-
up, mean (SD) * 
230.8 (195.3) 258.2 (232.5) 0.61 
DLI incidence/ 1000 
device days 
1.81 0.24 0.0002 
DLI incidence/ 100 
patient years 
65.9 8.8 0.0002 
*censored at protocol change, device removal/transplant, death or DLI  
Figure 2. Kaplan-Meier estimates for freedom from driveline infection for the two 
cohorts of patients undergoing different driveline management protocols; log-rank 
test, p=0.0003 
 
 
p=0.0003 
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We also analyzed the rate of DLI, incidence of DLI/1000 device days as well as 
log-rank survival analysis in the indication for transplant i.e. BTT vs. DT patients 
(no statistical difference) and the type of device implanted i.e. HeartMate II vs. 
HeartWare patients (no statistical difference). These results are shown in the 
Appendix Tables 1 and 2. We also conducted a sensitivity analysis of DLI 
occurrence including the indication for device implant as well as the type of 
device used assuming a potential 10% misclassification error and specificity of 
90%. In this sensitivity analysis, the only significant predictor of the outcome of 
DLI was the Group assignment (OR 0.00085, 95% 7.29e-07- 0.99294; p=0.05 
though a 95% CI that did not cross 1).  
Risk factors for development of DLI: In univariate analysis, patient presence in 
Group 2 was significantly lower in patients with a DLI (28.6% among patients with 
a DLI vs. 81.1% in those without a DLI, p<0.0001). There was a trend towards 
higher body mass index (BMI) in patients with DLIs vs. those that did not develop 
a DLI (mean BMI 28.62 vs. 25.6, p=0.059). We did not find an association with 
age, indication for VAD placement, INTERMACS category, device type, 
underlying cardiac disease, length of initial hospital stay, various co-morbidities 
including diabetes mellitus, post-operative need for hemodialysis, previous 
cardiac surgery or return to the operating room within 30 days of VAD placement. 
Baseline laboratory parameters at the time of VAD implantation including serum 
sodium, creatinine, white blood cell count, platelets, bilirubin, and albumin were 
similar in patients that developed DLI and those that did not. Patients that 
developed DLI had a higher hematocrit (mean 36.6 vs. 32.4, p=0.008) and lower 
INR (1.23 vs. 1.47; p=0.048) than those that did not develop a DLI in univariate 
analysis. 
The multivariate model included the driveline management group, BMI, 
hematocrit and INR; only the driveline management strategy was associated with 
development of DLI (OR 0.09, 95% CI 0.02-0.4, p=0.002) as shown in Table 3.  
Table 3. Univariate and multivariate analysis of factors associated with 
development of a driveline infection as the outcome (vs. no DLI) 
 Univariate analysis Multivariate analysis 
  p-value Odds 
ratio 
95% 
confidence 
interval 
p-value 
Placement in 
Group 2 
28.6% 
vs. 
81.1%  
<0.0001 0.09 0.02-0.4 0.002 
BMI (mean) 28.6 vs. 
25.6  
0.059   NS 
HCT, % 
(mean) 
36.6 vs. 
32.4 
0.008   NS  
INR  1.23 vs. 
1.47  
0.047   NS  
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We constructed an additional multivariate model including the driveline 
management group, indication for transplant, and type of device. Again, only the 
driveline management strategy was independently associated with DLI (OR 0.1, 
95% CI 0.03-0.5, p=0.003) and the indication for device placement (i.e. BTT, DT) 
as well as type of device placed were not associated with DLI.  
Microbiology: The majority of infections were caused by staphylococcal species. 
Microbiology of infections was as follows - methicillin-sensitive Staphylococcus 
aureus (6), methicillin-resistant S. aureus (2), coagulase-negative staphylococci 
(3), one with concurrent Propionibacterium acnes, Streptococcus viridans (1), 
Enterobacter cloacae (1), and no culture done (1).  
Clinical Outcome of DLI: Among all patients with DLI, concurrent pocket infection 
was present in 3, pump/cannula infection manifested as persistent bacteremia 
was present in 3, and concurrent mediastinitis in 2. Eight patients underwent 
surgical debridement and three required a device exchange secondary to 
infection. Majority of the patients were treated with 6-8 weeks of intravenous 
antibiotics, though 2 patients required IV antibiotics for >12 weeks, followed by 
varying lengths of oral suppression. Among the 14 patients with DLI, six (all were 
in Group 1) developed recurrent or new infection with a different organism often 
while still on suppressive antibiotics for their first infection. Three patients 
required device exchange for thrombosis following the onset of DLI. Five patients 
underwent successful heart transplantation following DLI onset.  
Discussion  
 
Percutaneous driveline infections are associated with significant morbidity and 
mortality, which is especially important since an increasing number of patients 
are now receiving VADs for long-term destination therapy. Driveline infection and 
bloodstream infections in VAD recipients has been associated with neurologic 
complications including cerebrovascular accidents.(11-13) Additionally, 
antecedent infection was noted in a third of VAD recipients prior to the 
development of device thrombosis and/or hemolysis.(14) Thus, device infection 
appears to be associated with greater downstream problems in addition to the 
already significant morbidity associated with device infection alone (including 
hospital readmission, long courses of intravenous antibiotics, patient discomfort, 
decreased quality of life, as well as repeat surgery). Despite all these issues and 
the fact that over 15,000 VADS have been implanted worldwide,(15) there is no 
consensus on the optimal driveline management protocol, as evidenced by a 
recent US survey of VAD centers.(7)  
 
Driveline management consists of driveline stabilization as well as the exit site 
cleansing and dressing. In this study, we demonstrated a significant decrease in 
DLI in our VAD population by a change in driveline management strategy. We 
demonstrated a decrease in DLIs from 1.81 to 0.24 events/ 1000 device days, 
which corresponds to a relative risk reduction of 85% and a number needed to 
treat of 2.82.  
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Silver sulfadiazine, along with chlorhexidine and triclosan, impregnated VAD 
driveline has been shown to decrease bacterial colonization in vivo.(16) The 
group from Columbia reported results from their use of a sterile silver gauze 
driveline dressing (SILVERCEL, Non-Adherent Antimicrobial Alginate Dressing) 
along with a Foley anchor device for driveline stabilization and also demonstrated 
a significant decrease in DLI with a relative risk reduction of 62.5%.(17) Of note, 
our new dressing change protocol did not include sterile technique, yet was 
associated with significantly fewer infections than our previous technique or 
published data among VAD centers.  This is important as adding sterile 
technique increases both cost and complexity of dressing changes.  
 
Traditionally an abdominal binder has been used to stabilize the driveline, 
despite the fact that it is frequently cumbersome and uncomfortable to use, 
potentially leading to decreased outpatient compliance as communicated by 
some of our patients. In our updated driveline management strategy, use of a 
small anchor made it easier for patients to use at home and potentially ensured 
better compliance, though we did not specifically assess compliance in this 
retrospective study. Additionally, decreasing the frequency of dressing changes 
to every 3 days decreased the physical manipulation of the site with decreased 
risk of introduction of infection.  
 
There are currently several approaches to minimizing driveline infections. These 
can be broadly categorized under surgical approaches, peri-operative antibiotic 
prophylaxis regimens, and approach to the driveline exit site management. The 
Driveline Silicone Interface Registry study demonstrated increased freedom from 
DLI in subjects implanted with a HeartMate II VAD in whom only the silicone 
portion of the DL was externalized; this is the approach used at our center 
consistently.(18) Results from the RESIST study were recently published in 
abstract form and showed ease of use and increased driveline stability with the 
use of a combination dressing kit that consisted of a proprietary “infection 
mitigation patch”, a clear dressing, tape and driveline anchor that was used 
specifically for patients with HeartMate II devices; additionally driveline dressing 
was changed almost weekly. (19) Unfortunately, there has not been a consensus 
approach to this process as of yet. We believe that reporting of individual studies 
should lead to larger multicenter trials to determine the optimal driveline 
management strategy. 
 
There are certain limitations inherent in our retrospective study design. The time 
periods of Groups 1 and 2 are not concurrent and thus there is a potential that 
the decreased rate of DLI could be related to an “era effect” due to our center’s 
increasing comfort level with the devices. However, the main surgeons 
performing the procedure did not change in this time period and the operative 
approach remained similar as well. Pre- and post-operative management did not 
change. An additional possibility is that with the change in driveline management 
protocol, there may have been increased focus on the driveline with potential 
change in compliance as well as individual technique; however we are unable to 
measure this from chart review alone. We made several driveline management 
changes at the same time and hence the effect of each individual change on its 
own is difficult to gauge. However, similar to the “bundle” effect in decreasing the 
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rates of infection in intravascular catheters, we demonstrate that the bundle of 
changes implemented led to a significant decrease in both the overall rate of 
infections as well as the incidence of driveline infections/ 1000 device days.  
 
In conclusion, there is a need for multicenter studies evaluating various aspects 
of driveline management including stabilization device, type of dressing and 
change frequency, as well as cleansing agent. We believe that this study 
provides important information that may be used to devise such a multicenter trial 
to determine the optimal driveline management strategy for VAD recipients.  
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 Appendix Table 1. Occurrence of driveline infections (DLI) in the bridge to 
transplant (BTT) vs destination therapy (DT) groups of patients. Follow-up 
censored at protocol change, device removal/transplant, death or DLI  
 BTT  (n=40) DT  (n=48) p-value 
No. of driveline 
infections 
4 (10%) 10 (20.8%) 0.24 
DLI incidence/ 1000 
device days 
0.52 0.7 0.32 
DLI incidence/ 100 
patient years 
18.9 25.5 0.32 
Log-rank for infection-
free survival analysis 
  0.52 
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Appendix Table 2. Occurrence of driveline infections (DLI) based on the type of 
device implanted (HeartMate II vs HeartWare). Follow-up censored at protocol 
change, device removal/transplant, death or DLI 
 
 HeartMate II 
(n=64) 
HeartWare 
(n=24) 
p-value 
No. of driveline 
infections 
13 (20.3%) 1 (4.2%) 0.1 
DLI incidence/ 1000 
device days 
0.74 0.23 0.12 
DLI incidence/ 100 
patient years 
26.8 8.3 0.12 
Log-rank for infection-
free survival analysis 
  1.64 
 
 
 
 
 
